PharmacoEconomics

Is it Time for Reporting Guidelines for Calibration Methods?
pp. 529-531(3)
Author: Cantor, Scott B.

Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
pp. 533-545(13)
Authors: Stout, Natasha K.; Knudsen, Amy B.; >Chung Yin Kong,; McMahon, Pamela M.; Gazelle, G. Scott

Societal and Patient Burden of Fibromyalgia Syndrome
pp. 547-559(13)
Authors: Annemans, Lieven; >Katell Le Lay,; Taïeb, Charles

Economic Evaluations in the EURONHEED: A Comparative Analysis
pp. 561-570(10)
Authors: Hutter, Florencia; Antoñanzas, Fernando

Costs of Illness in a Russian Cohort of Patients with Parkinson's Disease
pp. 571-584(14)
Authors: Winter, Yaroslav; >Sonja von Campenhausen,; Popov, Georgy; Reese, Jens P.; Klotsche, Jens; Bötzel, Kai; Gusev, Eugene; Oertel, Wolfgang H.; Dodel, Richard; Guekht, Alla

Cost Effectiveness of Fondaparinux in Non-ST-Elevation Acute Coronary Syndrome
pp. 585-595(11)
Authors: Latour-Perez, Jaime; de-Miguel-Balsa, Eva

Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan
pp. 597-608(12)
Authors: Shiroiwa, Takeru; Fukuda, Takashi; Shimozuma, Kojiro; Ohashi, Yasuo; Tsutani, Kiichiro

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease
pp. 609-621(13)
Authors: Yu, Andrew P.; Johnson, Scott; Wang, Si-Tien; Atanasov, Pavel; Tang, Jackson; Wu, Eric; Chao, Jingdong; Mulani, Parvez M.